Clene Inc. Files 8-K with Corporate Updates

TL;DR

Clene Inc. filed an 8-K on Oct 23, 2024, updating corporate info. Formerly Chelsea Worldwide Inc.

AI Summary

Clene Inc. filed an 8-K on October 23, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah, 84121, with a business phone number of 801-676-9695. The company was formerly known as Chelsea Worldwide Inc. until August 27, 2020.

Why It Matters

This 8-K filing provides essential corporate information and updates for Clene Inc., including its address and former name, which is important for investors and stakeholders to maintain accurate records.

Risk Assessment

Risk Level: low — This filing is primarily administrative, providing corporate details and exhibit information without disclosing significant financial events or strategic changes.

Key Players & Entities

• Clene Inc. (company) — Registrant
• October 23, 2024 (date) — Date of earliest event reported
• 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah, 84121 (location) — Principal executive offices address
• 801-676-9695 (phone_number) — Business phone number
• Chelsea Worldwide Inc. (company) — Former company name
• August 27, 2020 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
• $230.00 — rtieth of one share of Common Stock for $230.00 per share CLNNW The Nasdaq Capital

Filing Documents

• clnn20241022_8k.htm (8-K) — 28KB
• ex_736211.htm (EX-99.1) — 1KB
• ex991.jpg (GRAPHIC) — 324KB
• 0001437749-24-031805.txt ( ) — 622KB
• clnn-20241023.xsd (EX-101.SCH) — 4KB
• clnn-20241023_def.xml (EX-101.DEF) — 13KB
• clnn-20241023_lab.xml (EX-101.LAB) — 17KB
• clnn-20241023_pre.xml (EX-101.PRE) — 13KB
• clnn20241022_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 23, 2024, Clene Inc. (the "Company") presented the preliminary design for RESTORE-ALS, an international Phase 3 clinical trial of CNM-Au8 30 mg, at the 2024 Annual Northeast Amyotrophic Lateral Sclerosis Consortium ("NEALS") Meeting. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 RESTORE-ALS Presentation. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: October 23, 2024 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR